Systematic analysis and experimental validation of the prognostic and immunological effects of SPP1 tumor-associated macrophage features in colorectal cancer

Author:

Li Yizhang1,Yang Zhenwei1,Liu Jialong1,Wang Haizhou1,Wang Fan1,Zhang Hailin1,Zhao Qiu1,Liu Jing1

Affiliation:

1. Zhongnan Hospital of Wuhan University

Abstract

Abstract Purpose Tumor associated macrophages (TAM) influence colorectal cancer (CRC) development, and their clinical significance has been widely established. We intend to depict a full macrophage landscape in order to increase our understanding of CRC heterogeneity and give improved precision medicine techniques. Methods Use Seurat and Cellchat to conduct single cell analysis on GSE178341 to determine the interaction between cells and understand the influence of core cell subsets on immune response. SsGSEA was used to quantify the immune related cells of TCGA patients and further cluster them into subtypes. The effectiveness of combined COX and LASSO, SPP1 TAM characteristics in predicting prognosis was validated in several GEO datasets. Then, Cell line culture and Quantitative real-time PCR were used to validate the hub genes of SPP1 TAM features. Results and Conclusion To summarize, we built a more comprehensive macrophage atlas to highlight the wide range and heterogeneity of macrophages present in people at various MMR stages. SPP1 TAM is not only enriched in dMMR patients, but also shows two characteristics of immune response, which may explain the reason why some dMMR patients have poor response to immunotherapy. The prognosis model constructed by Hub DEG SPP1 related to it has different responses to immune response and chemotherapy drugs, which provides new clues to inhibit the potential efficacy of SPP1 TAM.

Publisher

Research Square Platform LLC

Reference44 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians;Bray F,2018

2. Worldwide variations in colorectal cancer;Center M;CA: a cancer journal for clinicians,2009

3. Intratumoral immunotherapy: using the tumor as the remedy;Marabelle A;Annals of oncology: official journal of the European Society for Medical Oncology,2017

4. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer;Yang Z;Frontiers in immunology,2022

5. Top 10 Challenges in Cancer Immunotherapy;Hegde P;Immunity,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3